Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(262 productos)
Mostrar 6 subcategorías más
Se han encontrado 1522 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Lck Inhibitor III
CAS:<p>Lck Inhibitor III, a potent inhibitor of Lck, exhibits an IC50 value of 867 nM.</p>Fórmula:C25H30N6O4Forma y color:SolidPeso molecular:478.54K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Fórmula:C15H13F2N7O2S2Pureza:99.12%Forma y color:SolidPeso molecular:425.44EGFR/BRAFV600E-IN-1
CAS:<p>EGFR/BRAFV600E-IN-1 inhibits EGFR (0.08 μM) & BRAFV600E (0.15 μM), affects A-549, MCF-7, Panc-1 & HT-29 (IC50: 0.79-1.3 μM).</p>Fórmula:C24H24ClN3O3Forma y color:SolidPeso molecular:437.92PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Fórmula:C18H26N6OForma y color:SolidPeso molecular:342.44ALK5-IN-30
CAS:<p>ALK5-IN-30 (EX-07) is a potent inhibitor of ALK with inhibitory effects on ALK5 (IC50< 10 nM) and TGFβ-R1 (IC50< 10 nM).</p>Fórmula:C24H25FN8Forma y color:SolidPeso molecular:444.51VEGFR-2-IN-27
CAS:<p>VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.</p>Fórmula:C25H21FN4O4Forma y color:SolidPeso molecular:460.46Sitravatinib malate
CAS:<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Fórmula:C37H35F2N5O9SPureza:98%Forma y color:SolidPeso molecular:763.76BIIB-057
CAS:<p>BIIB-057 is a selective Syk inhibitor.</p>Fórmula:C19H23N9OPureza:98%Forma y color:SolidPeso molecular:393.45Debio 0617B
CAS:<p>Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.</p>Fórmula:C28H23ClF3N7O2Forma y color:SolidPeso molecular:581.98Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Fórmula:C32H39N9O2Forma y color:SolidPeso molecular:581.71Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9FLT3-IN-6
CAS:<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Fórmula:C23H25N5O3Forma y color:SolidPeso molecular:419.48NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39Y 11
CAS:<p>focal adhesion kinase (FAK) inhibitor</p>Fórmula:C8H17BrN4OPureza:98%Forma y color:SolidPeso molecular:265.15EGFR-IN-46
CAS:<p>EGFR-IN-46: Potent EGFR/FAK inhibitor (IC50: 20.17 & 14.25 nM), curbs cancer cell growth, triggers apoptosis.</p>Fórmula:C27H32F3N3O3Forma y color:SolidPeso molecular:503.56EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64FAK/aurora kinase-IN-1
CAS:<p>FAK/aurora kinase-IN-1, a dual inhibitor of FAK and aurora kinase, has IC50 values of 6.61 nM and 0.91 nM respectively, and demonstrates anticancer effects (WO2018019252A1; compound 11) [1].</p>Fórmula:C23H24ClN7O3Forma y color:SolidPeso molecular:481.93JTV-519 free base
CAS:JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmicFórmula:C25H32N2O2SPureza:98%Forma y color:SolidPeso molecular:424.6PF-00337210
CAS:<p>PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.</p>Fórmula:C26H27N3O5Forma y color:SolidPeso molecular:461.51GW694590A
CAS:<p>GW694590A (UNC10112731) functions as a MYC protein stabilizer that enhances the levels of endogenous MYC protein. It also acts on receptor tyrosine kinases, inhibiting DDR2, KIT, and PDGFRα by 81%, 68%, and 67% at a concentration of 1 μM, respectively. As a protein kinase inhibitor, GW694590A affects both ATP-dependent and ATP-independent luciferases, potentially influencing the Fluc reporter gene [1].</p>Fórmula:C22H19N5O4Forma y color:SolidPeso molecular:417.42VEGFR-2-IN-20
CAS:<p>VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].</p>Fórmula:C20H20N4O3SForma y color:SolidPeso molecular:396.46FGFR2-IN-2
CAS:<p>FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.</p>Fórmula:C23H22N4OPureza:98.09%Forma y color:SolidPeso molecular:370.45EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6Depatuxizumab mafodotin
CAS:<p>Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].</p>Forma y color:LiquidTHS-044
CAS:<p>THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activity</p>Fórmula:C11H12F3N3O3Pureza:99.89%Forma y color:SolidPeso molecular:291.23KL-1156
CAS:<p>KL-1156 is an NF-κB inhibitor. It is also a lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.</p>Fórmula:C17H17NO4Pureza:98%Forma y color:SolidPeso molecular:299.32WDR5-IN-4
CAS:WIN site inhibitor 1 is a WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5) inhibitor (Kd: 0.1 nM), with anti-cancer activity.Fórmula:C25H22Cl2FN5OPureza:98%Forma y color:SolidPeso molecular:498.38VEGFR-2-IN-19
CAS:<p>VEGFR-2-IN-19 (15b) effectively inhibits VEGFR2, induces apoptosis, and increases oxidative stress, showing potential as an anticancer drug.</p>Fórmula:C21H19N3O2Forma y color:SolidPeso molecular:345.39FM19G11
CAS:<p>FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).</p>Fórmula:C23H17N3O8Pureza:99.70%Forma y color:SolidPeso molecular:463.4Glufanide disodium
CAS:<p>Glufanide disodium is an immunomodulator.</p>Fórmula:C16H17N3O5Na2Forma y color:SolidPeso molecular:377.3FLT3/ITD-IN-2
CAS:<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Fórmula:C23H26F3N7O2Forma y color:SolidPeso molecular:489.49R916562
CAS:R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.Fórmula:C26H30ClN9SPureza:98%Forma y color:SolidPeso molecular:536.09(R)-Afatinib
CAS:<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Fórmula:C24H25ClFN5O3Forma y color:SolidPeso molecular:485.94AZM475271
CAS:<p>AZM475271 is a potent and selective inhibitor of Src kinase(IC50 : 5 nM)</p>Fórmula:C23H27ClN4O3Pureza:99.78%Forma y color:SolidPeso molecular:442.94TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Forma y color:SolidPeso molecular:334.41SB-220025 trihydrochloride
CAS:<p>SB-220025 trihydrochloride is an effective and specific human p38 mitogen-activated protein kinase inhibitor.</p>Fórmula:C18H22Cl3FN6Pureza:98%Forma y color:SolidPeso molecular:447.77WB-308
CAS:<p>WB-308 is an EGFR inhibitor that acts by decreasing NSCLC cell proliferation and colony formation and causing G2/M arrest and apoptosis.</p>Fórmula:C19H17FN2OPureza:98%Forma y color:SolidPeso molecular:308.35Tyrphostin AG 568
CAS:<p>Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.</p>Fórmula:C13H9N5O2Pureza:98%Forma y color:SolidPeso molecular:267.24Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Forma y color:SolidPeso molecular:408.5TX-1918
CAS:<p>TX-1918, a tyrphostin, blocks eEF-2K to hinder HepG2, HCT116 cell growth.</p>Fórmula:C14H12O3Forma y color:SolidPeso molecular:228.24CGP60474
CAS:CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.Fórmula:C18H18ClN5OPureza:98.81%Forma y color:SolidPeso molecular:355.82FGFR2-IN-1
CAS:FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used to study FGFR2-associated cancers.Fórmula:C22H19N3O2Pureza:98.71%Forma y color:SolidPeso molecular:357.41KRCA-0713
CAS:<p>KRCA-0713 is a ALK inhibitor.</p>Fórmula:C26H32ClN5O3SPureza:98%Forma y color:SolidPeso molecular:530.08BGB659
CAS:<p>BGB659 is effective inhibitor of RAF.</p>Fórmula:C29H29F3N4O3Pureza:98%Forma y color:SolidPeso molecular:538.564-DAMP
CAS:<p>4-DAMP (4-DAMP methiodide) is a selective muscarinic M1 and M3 subtype receptor antagonist used in the study of allergic rhinitis and cardiovascular disease.</p>Fórmula:C21H26INO2Pureza:98%Forma y color:SolidPeso molecular:451.34BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OForma y color:SolidPeso molecular:417.51JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58Burixafor hydrobromide
CAS:<p>Burixafor hydrobromide is an oral CXCR4 blocker with anti-angiogenic properties, potentially treating choroid neovascularization.</p>Fórmula:C27H52BrN8O3PPureza:98%Forma y color:SolidPeso molecular:647.644Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Forma y color:SolidPeso molecular:362.86PF-06465469
CAS:<p>PF-06465469 is a covalent ITK inhibitor(IC50: 2 nM).</p>Fórmula:C30H33N7O2Pureza:98%Forma y color:SolidPeso molecular:523.63
